The U.S.
Borrowing heavily to become a leading generic drug company just as generic drug prices began tanking has been a drag on Teva Pharmaceutical (TEVA). …
Guggenheim’s Rohit Vanjani is not fazed by the updated PDUFA date for Teva’s fremanezumab- as long as the Celtrion facility re-inspection goes off without a hitch,
David Steinberg is out with a cautious note on Teva, believing much of the outlook is priced into the stock.
As Wall Street scrambles away from Teva after a sharp guidance miss for 2018, Oppenheimer’s Derek Archila shares his two (cautious) cents.
Generics price erosion; the ghost of debt maturation- BTIG’s Tim Chiang sees too many risks to hope for Teva’s recovery anymore.
Though Guggenheim’s Rohit Vanjani is not surprised by Teva’s amendment of financial leverage covenants, he sees this as a “watch” item.
BTIG’s Tim Chiang cautions that Momenta’s generic 40mg Copaxone is not the only rival coming for Teva.
Guggenheim’s Rohit Vanjani already is bracing for a roughly 50% share loss year-over-year for the Israeli pharma giant by 3Q:18.
In the foreseeable future, Maxim’s Jason Kolbert finds it unlikely TEVA will find itself in a place to boost its guidance.
